133 related articles for article (PubMed ID: 38218352)
1. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient.
Jachs M; Hartl L; Simbrunner B; Semmler G; Balcar L; Hofer BS; Schwarz M; Bauer D; Stättermayer AF; Pinter M; Trauner M; Reiberger T; Mandorfer M
J Hepatol; 2024 May; 80(5):744-752. PubMed ID: 38218352
[TBL] [Abstract][Full Text] [Related]
2. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.
Jachs M; Sandmann L; Hartl L; Tergast T; Schwarz M; Bauer DJM; Balcar L; Ehrenbauer A; Hofer BS; Cornberg M; Lenzen H; Deterding K; Trauner M; Mandorfer M; Wedemeyer H; Reiberger T; Maasoumy B
J Hepatol; 2024 Mar; ():. PubMed ID: 38479612
[TBL] [Abstract][Full Text] [Related]
3. Non-invasive tests for clinically significant portal hypertension after HCV cure.
Semmler G; Lens S; Meyer EL; Baiges A; Alvardo-Tapias E; Llop E; Tellez L; Schwabl P; Mauro E; Escudé L; Díez C; Ibañez-Samaniego L; Puente Á; Fortea JI; Abadía M; Zanetto A; Conthe A; Hernandez-Évole H; Luzko Scheid IS; Jia J; Yoshiji H; Francque SM; Tsochatzis EA; Russo FP; Crespo G; Forns X; Bañares R; Villanueva C; Hernández-Gea V; Reiberger T; Bosch J; García Pagán JC; Mandorfer M;
J Hepatol; 2022 Dec; 77(6):1573-1585. PubMed ID: 36063968
[TBL] [Abstract][Full Text] [Related]
4. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease.
Pons M; Augustin S; Scheiner B; Guillaume M; Rosselli M; Rodrigues SG; Stefanescu H; Ma MM; Mandorfer M; Mergeay-Fabre M; Procopet B; Schwabl P; Ferlitsch A; Semmler G; Berzigotti A; Tsochatzis E; Bureau C; Reiberger T; Bosch J; Abraldes JG; Genescà J
Am J Gastroenterol; 2021 Apr; 116(4):723-732. PubMed ID: 33982942
[TBL] [Abstract][Full Text] [Related]
5. Assessment of portal hypertension severity using machine learning models in patients with compensated cirrhosis.
Reiniš J; Petrenko O; Simbrunner B; Hofer BS; Schepis F; Scoppettuolo M; Saltini D; Indulti F; Guasconi T; Albillos A; Téllez L; Villanueva C; Brujats A; Garcia-Pagan JC; Perez-Campuzano V; Hernández-Gea V; Rautou PE; Moga L; Vanwolleghem T; Kwanten WJ; Francque S; Trebicka J; Gu W; Ferstl PG; Gluud LL; Bendtsen F; Møller S; Kubicek S; Mandorfer M; Reiberger T
J Hepatol; 2023 Feb; 78(2):390-400. PubMed ID: 36152767
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the Performance of Non-invasive Criteria for the Evaluation of Clinically Significant Portal Hypertension in Patients with Compensated Advanced Chronic Liver Disease.
Jindal A; Agarwal S; Sharma S; Kumar M; Saraya A; Sarin SK
Dig Dis Sci; 2023 May; 68(5):2149-2157. PubMed ID: 36562888
[TBL] [Abstract][Full Text] [Related]
7. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension.
Jachs M; Hartl L; Simbrunner B; Bauer D; Paternostro R; Scheiner B; Balcar L; Semmler G; Stättermayer AF; Pinter M; Quehenberger P; Trauner M; Reiberger T; Mandorfer M
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1854-1863.e10. PubMed ID: 36244661
[TBL] [Abstract][Full Text] [Related]
8. Baveno-VII criteria to predict decompensation and initiate non-selective beta-blocker in compensated advanced chronic liver disease patients.
Wong YJ; Zhaojin C; Tosetti G; Degasperi E; Sharma S; Agarwal S; Chuan L; Huak CY; Jia L; Xiaolong Q; Saraya A; Primignani M
Clin Mol Hepatol; 2023 Jan; 29(1):135-145. PubMed ID: 36064306
[TBL] [Abstract][Full Text] [Related]
9. Assessment of clinically significant portal hypertension by two-dimensional shear wave elastography.
Grgurevic I; Madir A; Trkulja V; Bozin T; Aralica G; Podrug K; Mikolaševic I; Tsochatzis E; O'Beirne J; Pinzani M
Eur J Clin Invest; 2022 Jun; 52(6):e13750. PubMed ID: 35040495
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of a single HVPG measurement and Doppler-ultrasound evaluation in patients with cirrhosis and portal hypertension.
Berzigotti A; Rossi V; Tiani C; Pierpaoli L; Zappoli P; Riili A; Serra C; Andreone P; Morelli MC; Golfieri R; Rossi C; Magalotti D; Zoli M
J Gastroenterol; 2011 May; 46(5):687-95. PubMed ID: 21213113
[TBL] [Abstract][Full Text] [Related]
11. ABC: a novel algorithm to stratify decompensation risk in patients with compensated advanced chronic liver disease (CHESS2108): an international, multicenter cohort study.
Liu C; Li J; Wong YJ; Xie Q; Hirooka M; Enomoto H; Kim TH; Hanafy AS; He R; Koizumi Y; Hiasa Y; Nishimura T; Iijima H; Jung YK; Yim HJ; Ma J; Zeng QL; Sarin SK; Qi X
Hepatol Int; 2022 Oct; 16(5):1105-1115. PubMed ID: 35606627
[TBL] [Abstract][Full Text] [Related]
12. Diabetes impairs the haemodynamic response to non-selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation.
Paternostro R; Jachs M; Hartl L; Simbrunner B; Scheiner B; Bauer D; Schwabl P; Semmler G; Trauner M; Mandorfer M; Reiberger T
Aliment Pharmacol Ther; 2023 Oct; 58(8):805-813. PubMed ID: 37519146
[TBL] [Abstract][Full Text] [Related]
13. Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension.
Semmler G; Hartl L; Mendoza YP; Simbrunner B; Jachs M; Balcar L; Schwarz M; Hofer BS; Fritz L; Schedlbauer A; Stopfer K; Neumayer D; Maurer J; Szymanski R; Meyer EL; Scheiner B; Quehenberger P; Trauner M; Aigner E; Berzigotti A; Reiberger T; Mandorfer M
Hepatology; 2024 Mar; ():. PubMed ID: 38447034
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
Lens S; Baiges A; Alvarado-Tapias E; LLop E; Martinez J; Fortea JI; Ibáñez-Samaniego L; Mariño Z; Rodríguez-Tajes S; Gallego A; Bañares R; Puente Á; Albillos A; Calleja JL; Torras X; Hernández-Gea V; Bosch J; Villanueva C; García-Pagán JC; Forns X
J Hepatol; 2020 Dec; 73(6):1415-1424. PubMed ID: 32535060
[TBL] [Abstract][Full Text] [Related]
15. [Risk factors of clinically significant portal hypertension in patients with compensated liver cirrhosis based on hepatic venous pressure gradient].
Jiang FR; Yan HD
Zhonghua Gan Zang Bing Za Zhi; 2021 Oct; 29(10):995-1000. PubMed ID: 34814395
[No Abstract] [Full Text] [Related]
16. Noninvasive predictors of clinically significant portal hypertension in NASH cirrhosis: Validation of ANTICIPATE models and development of a lab-based model.
Rabiee A; Deng Y; Ciarleglio M; Chan JL; Pons M; Genesca J; Garcia-Tsao G
Hepatol Commun; 2022 Dec; 6(12):3324-3334. PubMed ID: 36214066
[TBL] [Abstract][Full Text] [Related]
17. A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis.
Bosch J; Chung C; Carrasco-Zevallos OM; Harrison SA; Abdelmalek MF; Shiffman ML; Rockey DC; Shanis Z; Juyal D; Pokkalla H; Le QH; Resnick M; Montalto M; Beck AH; Wapinski I; Han L; Jia C; Goodman Z; Afdhal N; Myers RP; Sanyal AJ
Hepatology; 2021 Dec; 74(6):3146-3160. PubMed ID: 34333790
[TBL] [Abstract][Full Text] [Related]
18. The impact of hepatic steatosis on portal hypertension.
Semmler G; Scheiner B; Schwabl P; Bucsics T; Paternostro R; Chromy D; Stättermayer AF; Trauner M; Mandorfer M; Ferlitsch A; Reiberger T
PLoS One; 2019; 14(11):e0224506. PubMed ID: 31693695
[TBL] [Abstract][Full Text] [Related]
19. Non-invasive diagnosis and follow-up of portal hypertension.
Thabut D; Weil D; Bouzbib C; Rudler M; Cassinotto C; Castéra L; Serste T; Oberti F; Ganne-Carrié N; de Lédinghen V; Bourlière M; Bureau C
Clin Res Hepatol Gastroenterol; 2022 Oct; 46(8):101767. PubMed ID: 34332128
[TBL] [Abstract][Full Text] [Related]
20. The VITRO Score (Von Willebrand Factor Antigen/Thrombocyte Ratio) as a New Marker for Clinically Significant Portal Hypertension in Comparison to Other Non-Invasive Parameters of Fibrosis Including ELF Test.
Hametner S; Ferlitsch A; Ferlitsch M; Etschmaier A; Schöfl R; Ziachehabi A; Maieron A
PLoS One; 2016; 11(2):e0149230. PubMed ID: 26895398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
